



## Erratum

To cite this article: (2009) Erratum, Expert Opinion on Therapeutic Targets, 13:9, 1135-1135, DOI: [10.1517/14728220903223268](https://doi.org/10.1517/14728220903223268)

To link to this article: <https://doi.org/10.1517/14728220903223268>



Published online: 07 Aug 2009.



Submit your article to this journal [↗](#)



Article views: 288



View related articles [↗](#)

In the article “Selective Raf inhibition in cancer therapy”, published in the December 2007 issue of *Expert Opinion on Therapeutic Targets* (*Expert Opin Ther Targets* 2007;11(12):1587-1609) there is a structure in Figure 4 that is identified as PLX4032, a proprietary compound of Plexxikon. Plexxikon have identified this structure as being incorrect and would like to clarify this. The structure of PLX4032 has not been disclosed.

Informa Healthcare would like to apologise for any confusion caused.

